'Cancer Rates and Risks' Available

A Sneak Peek at 2025 ASCO From the GU Perspective

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

May 15th 2025

Teclistamab is Feasible for Select Elderly Patients with Multiple Myeloma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

$CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.$

Roman Fabbricatore

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Mary Katherine L. Anderson, MD;James P. Fagerland, MD;Samantha Kohn, MD, MS;Amy C. Cannella, MD;Benjamin A. Teply, MD

Expanding Horizons and Gaining Insights on T-DXd and Sacituzumab in Breast Cancer

This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.

ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

Shannon L. Puhalla, MD, delves into the clinical application, efficacy, and safety profiles of T-DXd and sacituzumab govitecan for patients with breast cancer.

Related Content

A Sneak Peek at 2025 ASCO From the GU Perspective

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

May 15th 2025

Teclistamab is Feasible for Select Elderly Patients with Multiple Myeloma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

$CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.$

Roman Fabbricatore

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Mary Katherine L. Anderson, MD;James P. Fagerland, MD;Samantha Kohn, MD, MS;Amy C. Cannella, MD;Benjamin A. Teply, MD

Expanding Horizons and Gaining Insights on T-DXd and Sacituzumab in Breast Cancer